Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: Digest version: JSN, JRS, and JCS Joint Working Group

Clinical and Experimental Nephrology

Volumn 17, Issue 4, 2013, Pages 441-479

  Ohno, Iwao ^a   Hayashi, Hiromitsu ^b   Aonuma, Kazutaka ^c   Horio, Masaru ^d   Kashihara, Naoki ^e   Okada, Hirokazu ^f   Komatsu, Yasuhiro ^g   Tamura, Shozo ^h   Awai, Kazuo ⁱ   Yamashita, Yasuyuki ^j   Kuwatsuru, Ryohei ^k   Hirayama, Atsushi ^l   Saito, Yoshihiko ^m   Murohara, Toyoaki ⁿ   Tamaki, Nagara ^o   Sato, Akira ^c   Takayama, Tadateru ^l   Imai, Enyu ⁿ   Yasuda, Yoshinari ⁿ   Koya, Daisuke ^p   Tsubakihara, Yoshiharu ^d   Horie, Shigeo ^q   Korogi, Yukunori ^r   Narumi, Yoshifumi ^s   Hayakawa, Katsumi ^t   Daida, Hiroyuki ^k   Node, Koichi ^u   Kubota, Isao ^v   more..

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^h UNIVERSITY OF MIYAZAKI   (Japan)

ⁱ HIROSHIMA UNIVERSITY   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

^k JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m NARA MEDICAL UNIVERSITY   (Japan)

ⁿ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o HOKKAIDO UNIVERSITY   (Japan)

^p KANAZAWA MEDICAL UNIVERSITY   (Japan)

^q TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^s OSAKA MEDICAL COLLEGE   (Japan)

^t KYOTO CITY HOSPITAL   (Japan)

^u SAGA UNIVERSITY   (Japan)

^v YAMAGATA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; BIGUANIDE DERIVATIVE; DIURETIC AGENT; DOPAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOTROLAN; IOVERSOL; IOXILAN; LOOP DIURETIC AGENT; MEGLUMINE DIATRIZOATE; MEGLUMINE IOTALAMATE; MEGLUMINE IOTROXATE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSCOPE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AGING; ANGIOCARDIOGRAPHY; CHOLESTEROL EMBOLISM; CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DRUG USE; FLUID INTAKE; HEMODIALYSIS; HEMOFILTRATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INVASIVE PROCEDURE; LACTIC ACIDOSIS; LOW DRUG DOSE; NON INVASIVE PROCEDURE; OSMOLARITY; OUTPATIENT; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROGNOSIS; PROPHYLAXIS; REHYDRATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ACUTE KIDNEY INJURY; BIGUANIDES; CONTRAST MEDIA; CREATININE; FLUID THERAPY; HUMANS; IODINE RADIOISOTOPES; KIDNEY DISEASES; OSMOLAR CONCENTRATION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84883264266     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0843-3     Document Type: Review

References (196)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;2013(3):19-62.
2. Lameire N, Adam A, Becker CR, Davidson C, McCullough PA, Stacul F, CIN Consensus Working Panel, et al. Baseline renal function screening. Am J Cardiol. 2006;98:21K-6K [VI].
3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-9 [IVb].
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-64 [IVb].
5. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol. 2008;3:1274-81 [IVa].
6. Kim SM, Cha RH, Lee JP, Kim DK, Oh KH, Joo KW, et al. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am J Kidney Dis. 2010;55:1018-25 [IVb].
7. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR), et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527-41 [VI].
8. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419-28 [I].
9. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254-61 [II].
10. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320:143-9 [III].
11. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-9 [I].
12. Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine. Ann Acad Med Singapore. 2010;39:374-80 [IVa].
13. La Manna G, Pancaldi LG, Capecchi A, Maska E, Comai G, Cappuccilli ML, et al. Risk for contrast nephropathy in patients undergoing coronarography. Artif Organs. 2010;34:E193-9 [IVb].
14. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant. 2010;25:759-64 [IVb].
15. Saudan P, Muller H, Feraille E, Martin PY, Mach F. Renin-angiotensin system blockade and contrast-induced renal toxicity. J Nephrol. 2008;21:681-5 [IVa].
16. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008;40:749-55 [IVa].
17. Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69:135-40.
18. Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taqylor DA, Teo KK. Forced euvolemic diuretic with mannitol and furosecemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54:602-9 [I].
19. Solomon R, Wener C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decrease in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-20 [II].
20. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, REMEDIAL II Investigators, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124:1260-9 [II].
21. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5:90-7 [II].
22. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164:881-9 [IVb].
23. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379-86 [V].
24. Jain V, Sharma D, Prabhakar H, Dash HH. Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity. Eur J Anaesthesiol. 2008;25:166-7 [V].
25. Safadi R, Dranitzki-Elhalel M, Popovtzer M, Ben-Yehuda A. Metformin-induced lactic acidosis associated with acute renal failure. Am J Nephrol. 1996;16:520-2 [V].
26. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255:179-87 [V].
27. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media - a dangerous combination? Clin Radiol. 1999;54:29-33 [I].
28. Rasuli P, Hammond DI. Metformin and contrast media: where is the conflict? Can Assoc Radiol J. 1998;49:161-6 [VI].
29. Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254:261-9 [I].
30. Khurana R, Malik IS. Metformin: safety in cardiac patients. Heart. 2010;96:99-102 [VI].
31. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia. 2005;48:2454-9 [VI].
32. Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol. 2009;29:136-44 [IVa].
33. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc. 2008;83:1095-100 [IVa].
34. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-8 [IVa].
35. Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105:624-8 [IVa].
36. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-75 [IVa].
37. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780-5 [IVa].
38. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-75 [IVa].
39. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170-7 [IVa].
40. Heitmeyer C, Hölscher B, Fobker M, Breithardt G, Hausberg M, Reinecke H. Prognostic value of different laboratory measures of renal function for long-term mortality after contrast media-associated renal impairment. Clin Cardiol. 2010;33:E51-9 [IVa].
41. Jujo K, Yamaguchi J, Obayashi K, Suzuki K, Sekiguchi H, Nagashima M, et al. Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial Infarction undergoing emergent coronary angiography. J Cardiol. 2006;48:9-16 (in Japanese) [IVa].
42. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256:21-8 [IVa].
43. Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008;3:1242-3 [VI].
44. Matsushima K, Peng M, Schaefer EW, Pruitt JH, Kashuk JL, Frankel HL. Posttraumatic contrast-induced acute kidney injury: minimal consequences or significant threat? J Trauma. 2011;70:415-9 [IVa].
45. Rashid AH, Brieva JL, Stokes B. Incidence of contrast-induced nephropathy in intensive care patients undergoing computerised tomography and prevalence of risk factors. Anaesth Intensive Care. 2009;37:968-75 [IVa].
46. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant. 2006;21:1040-5 [IVa].
47. Dittrich E, Puttinger H, Schillinger M, Lang I, Stefenelli T, Hörl WH, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients - a prospective study. Nephrol Dial Transplant. 2006;21:1334-9 [IVa].
48. Brown JR, DeVries JT, Piper WD, Robb JF, Hearne MJ, Ver Lee PM, Northern New England Cardiovascular Disease Study Group, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J. 2008;155:260-6 [IVa].
49. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-9 [II].
50. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:S11-5 [VI].
51. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649-52 [IVb].
52. Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49:658-67 [V].
53. Brown JR, Robb JF, Block CA, Schoolwerth AC, Kaplan AV, O'Connor GT, et al. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv. 2010;3:346-50 [II].
54. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171-8 [I].
55. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-9 [II].
56. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Investigators of the CARE Study, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-96 [II].
57. Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250:68-86 [I].
58. Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int. 2006;70:1811-7 [IVb].
59. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, et al. Focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;2009(120):2271-306.
60. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:2022-60.
61. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-651.
62. Chou SH, Wang ZJ, Kuo J, Cabarrus M, Fu Y, Aslam R, et al. Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration. Eur J Radiol. 2011;80:378-86 [IVb].
63. Lufft V, Lufft LH, Fels LM, Baiyee DE, Tusch G, Galanski M, et al. Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis. 2002;40:236-42 [II].
64. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol. 2000;54:11-4 [IVb].
65. Tepel M, van der Geit M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-4 [II].
66. Becker CR, Reiser MF. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol. 2005;40:672-5 [IVa].
67. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computer tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41:815-21 [II].
68. Thomsen HS, Morcos SK, Earley CM, Grazioli L, Bonomo L, Ni Z, Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study, et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170-8 [II].
69. Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. Am J Roentgenol. 2008;191:151-7 [II].
70. Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248:97-105 [II].
71. Gallotti A, Uggeri F, Favilla A, Cabrini M, de Haën C. The chemistry of iomeprol and physico-chemical properties of its aqueous solutions and pharmaceutical formulations. Eur J Radiol. 1994;18(Suppl 1):S1-12 [VI].
72. Sovak M. The need for improved contrast media. Ioxilan: updating design theory. Invest Radiol. 1988;23(Suppl 1):S79-83 [VI].
73. Shiraki K, Otani H, Ohno Z, Takeuchi R, Hirai M, Murata K, et al. Case study of contrast-induced nephropathy using cardiac catheterization. Jpn Circ J. 2001;65(Suppl III):750 (in Japanese) [IVb].
74. Fujisaki K, Nakayama M, Yoshimitsu T, Doi T, Tanaka R, Yamada A, et al. Incidence of contrast-induced nephropathy using cardiac catheterization: a case report. Jpn J Nephrol. 2002;44:315 (in Japanese) [IVb].
75. Abe M, Kimura T, Morimoto T, Furukawa Y, Kita T. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J. 2009;73:1518-22 [IVb].
76. Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, NHLBI Dynamic Registry Investigators, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584-90 [IVb].
77. Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58:907-14 [IVb].
78. Chong E, Poh KK, Liang S, Soon CY, Tan HC. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol. 2010;23:451-9 [IVa].
79. Machino-Ohtsuka T, Seo Y, Ishizu T, Sekiguchi Y, Sato A, Tada H, et al. Combined assessment of carotid vulnerable plaque, renal insufficiency, eosinophilia, and hs-CRP for predicting risky aortic plaque of cholesterol crystal embolism. Circ J. 2010;74:51-8 [IVb].
80. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A, Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003;42:211-6 [IVb].
81. Funabiki K, Masuoka H, Shimizu H, Emi Y, Mori T, Ito M, et al. Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature. Jpn Heart J. 2003;44:767-74 [IVb].
82. Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12:1781-7 [IVb].
83. Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36:1089-109 [IVb].
84. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840-50 [IVb].
85. Thadhani RI, Camargo CA Jr, Xavier RJ, Fang LS, Bazari H. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore). 1995;74:350-8 [IVb].
86. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38:769-84 [IVb].
87. Oleinik A, Romero JM, Schwab K, Lev MH, Jhawar N, Delgado Almandoz JE, et al. CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy. Stroke. 2009;40:2393-7 [IVa].
88. Herts BR, Schneider E, Obuchowski N, Poggio E, Jain A, Baker ME. Probability of reduced renal function after contrast-enhanced CT: a model based on serum creatinine level, patient age, and estimated glomerular filtration rate. AJR Am J Roentgenol. 2009;193:494-500 [IVb].
89. Hipp A, Desai S, Lopez C, Sinert R. The incidence of contrast-induced nephropathy in trauma patients. Eur J Emerg Med. 2008;15:134-9 [IVa].
90. Lencioni R, Fattori R, Morana G, Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) - a clinical problem in daily practice? A multicenter observational study. Acta Radiol. 2010;51:741-50 [IVa].
91. Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Isr Med Assoc J. 2009;11:460-4 [IVb].
92. Cramer BC, Parfrey PS, Hutchinson TA, Baran D, Melanson DM, Ethier RE, et al. Renal function following infusion of radiologic contrast material. A prospective controlled study. Arch Intern Med. 1985;145:87-9 [IVa].
93. Langner S, Stumpe S, Kirsch M, Petrik M. No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium. AJNR Am J Neuroradiol. 2008;29:1525-9 [IVa].
94. Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner G. Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in mL/min. Acta Radiol. 2005;46:830-42 [I].
95. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol. 2008;51:89-90 [V].
96. Abujudeh HH, Gee MS, Kaewiai R. In emergency situations, should serum creatinine be checked in all patients before performing second contrast CT examinations within 24 hours? J Am Coll Radiol. 2009;6:268-73 [V].
97. Trivedi H, Foley WD. Contrast-induced nephropathy after a second contrast exposure. Ren Fail. 2010;32:796-801 [V].
98. Hopyan JJ, Gladstone DJ, Mallia G, Schiff J, Fox AJ, Symons SP, et al. Renal safety of CT angiography and perfusion imaging in the emergency evaluation of acute stroke. AJNR Am J Neuroradiol. 2008;29:1826-30 [V].
99. Lima FO, Lev MH, Levy RA, Silva GS, Ebril M, de Camargo EC, et al. Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy. AJNR Am J Neuroradiol. 2010;31:817-21 [IVa].
100. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010;5:4-9 [V].
101. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography. Am J Med. 1980;68:43-6 [V].
102. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol. 1981;136:859-61 [V].
103. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29-34 [II].
104. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007;49:1283-8 [II].
105. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-36 [II].
106. Wróbel W, Sinkiewicz W, Gordon M, WoÅ̈niak- WiÅniewska A. Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions. Kardiol Pol. 2010;68:1015-20 [II].
107. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114:1570-4 [II].
108. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006;21:2120-6 [II].
109. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009;151:631-8 [I].
110. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23 [I].
111. Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol. 2009;41:617-27 [I].
112. Hogan SE, L'Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156:414-21 [I].
113. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120:742-8 [I].
114. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:617-27 [I].
115. Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2010;74:288-96 [I].
116. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300:1038-46 [II].
117. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1584-92 [I].
118. Ueda H, Yamada T, Masuda M, Okuyama Y, Morita T, Furukawa Y, et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol. 2011;107:1163-7 [II].
119. Tamura A, Goto Y, Miyamoto K, Naono S, Kawano Y, Kotoku M, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol. 2009;104:921-5 [II].
120. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol. 2011;107:1604-8 [II].
121. Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011;107:1447-52 [II].
122. Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54:610-8 [II].
123. Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol. 2010;23:216-23 [II].
124. Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009;22:556-63 [II].
125. Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699-702 [II].
126. Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62:1-7 [II].
127. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599-604.
128. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol. 1997;272:F292-8 [VI].
129. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422-9 [II].
130. Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005;17:80-4 [II].
131. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-82 [II].
132. Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250-9 [II].
133. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284-94 [I].
134. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(874):e9-15 [I].
135. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140-5 [I].
136. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366-74 [I].
137. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761-9 [I].
138. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32 [I].
139. Anderson SM, Park ZH, Patel RV. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy. Ann Pharmacother. 2011;45:101-7 [I].
140. Trivedi H. Is there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Ann Intern Med. 2008;149:213 (author reply 215-216 [VI]).
141. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407-10 [VI].
142. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007;189:687-92 [VI].
143. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84:170-9 [VI].
144. Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol. 1991;261:F1102-9 [VI].
145. Meyer-Lehnert H, Bayer T, Predel HG, Glanzer K, Kramer HJ. Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure. Klin Wochenschr. 1991;69:895-903 [VI].
146. Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Intensive Care Med. 1996;22:230-6 [IVa].
147. Kurnik BR, Weisberg LS, Cuttler IM, Kurnik PB. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med. 1990;116:27-36 [II].
148. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-65 [II].
149. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674-80 [II].
150. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53:1040-6 [II].
151. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiol. 2010;6:641-8 [II].
152. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-42 [II].
153. Naidu KA. Vitamin C in human health and disease is still a mystery? An overview. Nutr J. 2003;2:7-16 [II].
154. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-7 [II].
155. Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2006;82:1381-90 [VI].
156. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843-9 [IVa].
157. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279-85 [IVa].
158. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011;33:344-51 [I].
159. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol. 2011;153:323-5 [I].
160. Vogt B, Ferrari P, Schönholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001;111:692-8 [I].
161. Sterner G, Frennby B, Kurkus J, Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol. 2000;34:323-6 [I].
162. Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant. 1998;13:358-62 [I].
163. Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003;60:176-82 [I].
164. Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol. 2007;96:130-9 [I].
165. Shiragami K, Fujii Z, Sakumura T, Shibuya M, Takahashi N, Yano M, et al. Effect of a contrast agent on long-term renal function and the efficacy of prophylactic hemodiafiltration. Circ J. 2008;72:427-33 [I].
166. Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007;50:1015-20 [I].
167. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-40 [I].
168. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119:155-62 [I].
169. Song K, Jiang S, Shi Y, Shen H, Shi X, Jing D. Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Nephrol. 2010;32:497-504 [II].
170. Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweiz Med Wochenschr. 1996;126:666-73 [II].
171. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant. 1997;12:2592-6 [II].
172. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-53 [IVa].
173. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL, High-Dose Furosemide in Acute Renal Failure Study Group. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004;44:402-9 [II].
174. Uchino S, Doig GS, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Diuretics and mortality in acute renal failure. Crit Care Med. 2004;32:1669-77 [IVa].
175. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006;333:420 [I].
176. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc. 2007;9:60-8 [I].
177. Payen D, de Pont AC, Sakr Y, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74 [IVb].
178. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422-7 [IVa].
179. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-3 [II].
180. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000;356:2139-43 [II].
181. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526-31 [I].
182. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510-24 [I].
183. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med. 2002;28:877-83 [I].
184. Ichai C, Passeron C, Carles M, Bouregba M, Grimaud D. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in haemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med. 2000;28:1329-35 [II].
185. Lauschke A, Teichgraber UK, Frei U, Eckardt KU. Low-dose dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006;69:1669-74 [II].
186. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, et al. Anaritide in acute tubular necrosis. N Engl J Med. 1997;336:828-34 [II].
187. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, et al. Atrial natriuretic factor in oliguric acute renal failure. Am J Kidney Dis. 2000;36:767-74 [II].
188. Swaerd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med. 2004;32:1310-5 [II].
189. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:261-72 [I].
190. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002;30:2205-11 [II].
191. Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915-9 [IVa].
192. Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jabber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008;52:272-84 [I].
193. Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TW. Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int. 2010;14:11-7 [IVa].
194. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care. 2009;24:129-40 [IVa].
195. Shiao CC, Wu VC, Li WY, Lin YF, Hu FC, Young GH, National Taiwan University Surgical Intensive Care Unit-Associated Renal Failure Study Group, et al. Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. Crit Care. 2009;13:R171 [IVa].
196. Iyem H, Tavli M, Akcicek F, Bueket S. Importance of early dialysis for acute renal failure after an open-heart surgery. Hemodial Int. 2009;13:55-61 [IVa].